Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-HIV-1 Env VHH antibody
- Development stage
- Preclinical
- Lead developer
- COGNANO
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Topical, Rectal, Intracellular, Microbial, Gene Therapy
01
Overview
This preclinical-stage VHH antibody, also known as a nanobody, is being developed by COGNANOUS for the treatment of HIV-1 infection and AIDS. Derived from camelid heavy-chain-only antibodies, VHH antibodies are significantly smaller than conventional antibodies, allowing them to bind to recessed or hidden epitopes on the HIV-1 Envelope (Env) protein. The Env protein is the primary target for neutralizing antibodies as it mediates viral attachment and fusion with host cell membranes. By targeting conserved regions of the Env spike, this nanobody is designed to block viral entry and neutralize a broad range of HIV-1 strains.
- Other names
- anti-Env VHH antibodyHIV-1 Env-VHH antibodyHIV1 Env-VHH antibodyHIV 1 Env-VHH antibodyCOGNANOUS HIV-1 nanobody
02
Targets
Env (HIV-1 envelope glycoprotein)
Beyond the preview
Go deeper on anti-HIV-1 Env VHH antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-HIV-1 Env VHH antibody.